Vimpat and Affect lability - a phase IV clinical study of FDA data

Summary:

Affect lability is reported as a side effect among people who take Vimpat (lacosamide), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Keppra, and have Simple partial seizures.

The phase IV clinical study analyzes which people have Affect lability when taking Vimpat. It is created by eHealthMe based on reports of 20,279 people who have side effects when taking Vimpat from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.

What is Affect lability?

Affect lability (emotional incontinence) is found to be associated with 693 drugs and 827 conditions by eHealthMe. Check the latest studies of Affect lability.

On Feb, 01, 2026

20,279 people reported to have side effects when taking Vimpat.
Among them, 21 people (0.1%) have Affect lability.

Among these 21 people:

How long have people been on Vimpat when they have Affect lability? *

What is the gender of people who have Affect lability when taking Vimpat? *

female: 57.89 %
male: 42.11 %

What is the age of people who have Affect lability when taking Vimpat? *

What are other drugs people take besides Vimpat? *

What are other side effects people have besides Affect lability? *

Memory Loss: 13 people, 61.90%
Psychotic Disorder: 10 people, 47.62%
Speech Impairment (Adult) (inability to speak (adult)): 10 people, 47.62%
Drowsiness: 10 people, 47.62%
Malaise (a feeling of general discomfort or uneasiness): 9 people, 42.86%
Fatigue (feeling of tiredness): 9 people, 42.86%
Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 8 people, 38.10%
Confusional State: 3 people, 14.29%
Weight Increased: 3 people, 14.29%
Weakness: 3 people, 14.29%

What are the existing conditions these people have? *

Simple Partial Seizures (seizures which affect only a small region of the brain): 9 people, 42.86%
Psychiatric Symptom: 8 people, 38.10%
Partial Seizures (seizures which affect only a part of the brain at onset): 7 people, 33.33%
Complex Partial Seizures (epileptic seizure): 2 people, 9.52%
Temporal Lobe Epilepsy (a term that refers to a condition where seizures are generated in the portion of the brain called the temporal lobe): 1 person, 4.76%
Iga Nephropathy (kidney disease- condition prevents the kidneys from filtering waste): 1 person, 4.76%
Depression: 1 person, 4.76%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and have Affect lability?

- Check whether Affect lability is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimpat:

Vimpat (20,831 reports)

Affect lability treatments and more:

Affect lability (13,491 reports)

Browse all side effects of Vimpat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Affect lability:

Affect lability (693 drugs)

Browse all the conditions that are associated with Affect lability:

Affect lability (827 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lacosamide (the active ingredients of Vimpat) and Vimpat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.